Amyris Inc. (NASDAQ:AMRS) major shareholder (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of the firm’s stock in a transaction dated Monday, October 17th. The stock was sold at an average price of $0.83, for a total value of $1,909,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Amyris Inc. (NASDAQ:AMRS) opened at 1.08 on Wednesday. Amyris Inc. has a 12-month low of $0.31 and a 12-month high of $1.85. The firm’s market cap is $253.82 million. The company’s 50 day moving average price is $0.55 and its 200-day moving average price is $0.59.
Amyris (NASDAQ:AMRS) last posted its earnings results on Thursday, August 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.06. The firm had revenue of $9.60 million for the quarter, compared to analyst estimates of $15.23 million. During the same period in the previous year, the company posted ($0.47) EPS. Amyris’s revenue was up 23.1% on a year-over-year basis. On average, equities research analysts anticipate that Amyris Inc. will post ($0.20) EPS for the current year.
A number of institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in shares of Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock valued at $331,000 after buying an additional 30,958 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Amyris during the first quarter valued at $269,000. Finally, Vanguard Group Inc. increased its stake in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock valued at $766,000 after buying an additional 311,142 shares during the period. 35.68% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have weighed in on AMRS. Singular Research reissued a “buy” rating and issued a $2.80 price target on shares of Amyris in a report on Wednesday, September 28th. Zacks Investment Research raised Amyris from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a report on Tuesday, September 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Amyris presently has a consensus rating of “Buy” and an average price target of $2.66.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.